FGF12 and endometrioid stromal sarcoma: FGF receptor inhibitors, such as FGFR tyrosine kinase inhibitors (49), have shown efficacy in various cancers with aberrant FGF signaling and may represent a potential treatment avenue for ESS patients with high FGF12 expression.